3.78
0.03 (0.80%)
| Penutupan Terdahulu | 3.75 |
| Buka | 3.76 |
| Jumlah Dagangan | 733,697 |
| Purata Dagangan (3B) | 915,984 |
| Modal Pasaran | 258,630,624 |
| Harga / Buku (P/B) | 1.25 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| EPS Cair (TTM) | -2.18 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.86% |
| Nisbah Semasa (MRQ) | 8.91 |
| Aliran Tunai Operasi (OCF TTM) | -105.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -61.14 M |
| Pulangan Atas Aset (ROA TTM) | -35.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.68% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Care Facilities (US) | Menurun | Bercampur |
| Medical Care Facilities (Global) | Menurun | Bercampur | |
| Stok | COMPASS Pathways Plc - American | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.38 |
|
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. |
|
| Sektor | Healthcare |
| Industri | Medical Care Facilities |
| % Dimiliki oleh Orang Dalam | 22.15% |
| % Dimiliki oleh Institusi | 48.33% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (HC Wainwright & Co., 1,487.30%) | Beli |
| Median | 18.00 (376.19%) | |
| Rendah | 12.00 (Maxim Group, 217.46%) | Beli |
| Purata | 30.00 (693.65%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 4.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Nov 2024 | 60.00 (1,487.30%) | Beli | 4.75 |
| Maxim Group | 01 Nov 2024 | 12.00 (217.46%) | Beli | 4.75 |
| RBC Capital | 01 Nov 2024 | 18.00 (376.19%) | Beli | 4.75 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Jan 2025 | Pengumuman | Compass Pathways Announces Pricing of Underwritten Offering |
| 18 Dec 2024 | Pengumuman | Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) |
| 25 Nov 2024 | Pengumuman | Compass Pathways to Participate in December Investor Conferences |
| 31 Oct 2024 | Pengumuman | Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates |
| 24 Oct 2024 | Pengumuman | Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |